Tailoring anti-TNF therapy in IBD: Drug levels and disease activity

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 4, 2014, Pages 243-255

  Ben Horin, Shomron ^a   Chowers, Yehuda ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DRUG ANTIBODY; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

CROHN DISEASE; DISEASE ACTIVITY; DISTRIBUTION VOLUME; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFLAMMATORY BOWEL DISEASE; PRIORITY JOURNAL; REMISSION; REVIEW; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; INFLAMMATORY BOWEL DISEASES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFLAMMATORY BOWEL DISEASES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84898005882     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2013.253     Document Type: Review

References (149)

1. Hanauer, S. et al. Maintenance Infliximab for Crohn's Disease: The ACCENT 1 randomized trial. Lancet 359, 1541-1549 (2002).
2. Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462-2476 (2005).
3. Sands, B. E. et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 350, 876-885 (2004).
4. D'Haens, G. R. et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: When to start, when to stop, which drug to choose, and how to predict response? Am. J. Gastroenterol. 106, 199-212 (2011).
5. Colombel, J. F. et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 132, 52-65 (2007).
6. Peake, S. T. et al. Mechanisms of action of anti tumor necrosis factor α agents in Crohn's disease. Inflamm. Bowel Dis. 19, 1546-1555 (2013).
7. Nesbitt, A. et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-Tumor necrosis factor α agents. Inflamm. Bowel Dis. 13, 1323-1332 (2007).
8. Johnston, A. & Holt, D. W. Therapeutic drug monitoring of immunosuppressant drugs. Br. J. Clin. Pharmacol. 47, 339-350 (1999).
9. Maser, E. A., Villela, R., Silverberg, M. S. & Greenberg, G. R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin. Gastroenterol. Hepatol. 4, 1248-1254 (2006).
10. Karmiris, K. et al. Influence of trough serum levels and immunogenicity on long-Term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 137, 1628-1640 (2009).
11. Hanauer, S. B. et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2, 542-553 (2004).
12. Seow, C. H. et al. Trough serum infliximab: A predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 59, 49-54 (2010).
13. Chiu, Y. L. et al. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm. Bowel Dis. 19, 1112-1122 (2013).
14. Feagan, B. G. et al. Novel Infliximab (IFX) and antibody to infliximab (ATI) assays are predictive of disease activity in patients with Crohn's disease (CD). Gastroenterology 142 (Suppl. 1) S114 (2012).
15. Ben-Bassat, O., Romanova, A., Lacono, A., Irwin, S. P. & Greenberg, G. R. Association of serum infliximab and antibodies to infliximab to long-Term clinical outcome and mucosal healing in Crohn's disease. Gastroenterology 142 (Suppl. 1), S775 (2012).
16. Yarur, A. J. et al. Serum adalimumab levels and antibodies correlate with endoscopic intestinal inflammation and inflammatory markers in patients with inflammatory bowel disease. Gastroenterology 142 (Suppl. 1), S774-S775 (2012).
17. Mazor, Y. et al. Evaluating adalimumab drug and antibody levels as predictors of clinical and laboratory response in Crohn's disease patients. Gastroenterology 144 (Suppl. 1), S780 (2013).
18. Steenholdt, C., Bendtzen, K., Brynskov, J., Thomsen, O. O. & Ainsworth, M. A. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand. J. Gastroenterol. 46, 310-318 (2011).
19. Sandborn, W. J. et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin. Gastroenterol. Hepatol. 8, 688-695 (2010).
20. Schreiber, S. et al. Randomised clinical trial: Certolizumab pegol for fistulas in Crohn's disease-subgroup results from a placebo-controlled study. Aliment. Pharmacol. Ther. 33, 185-193 (2011).
21. Hyams, J. et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin. Gastroenterol. Hepatol. 10, 391-399 (2012).
22. Pillot, C., Chevaux, J. B., Bigard, M. A. & Peyrin Biroulet, L. Infliximab 10 mg/kg every 3 weeks for Crohn's disease. Am. J. Gastroenterol. 105, 2509-2510 (2010).
23. Baert, F. et al. Influence of immunogenicity on the long-Term efficacy of Infliximab in Crohn's disease. N. Engl. J. Med. 348, 601-608 (2003).
24. Ben-Horin, S. et al. The immunogenic part of Infliximab is the F(ab')2 fragment, but measuring antibodies to the intact Infliximab molecule is more clinically useful. Gut 60, 41-48 (2011).
25. van Schouwenburg, P. A. et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann. Rheum. Dis. 72, 104-109 (2013).
26. Yamada, A., Sono, K., Hosoe, N., Takada, N. & Suzuki, Y. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm. Bowel Dis. 16, 1898-1904 (2010).
27. Rojas, J. R. et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 313, 578-585 (2005).
28. West, R. L. et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment. Pharmacol. Ther. 28, 1122-1126 (2008).
29. Sandborn, W. J. et al. Subcutaneous golimumab maintains clinical response in patients with moderate to severe ulcerative colitis. Gastroenterology http://dx.doi.org/10.1053/j.gastro.2013.06.010.
30. Ainsworth, M. A., Bendtzen, K. & Brynskov, J. Tumor necrosis factor-α binding capacity and anti-Infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of Infliximab in Crohn's disease. Am. J. Gastroenterol. 103, 944-948 (2008).
31. Cassinotti, A. & Travis, S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: A critical systematic review. Inflamm. Bowel Dis. 15, 1264-1275 (2009).
32. Nanda, K. S., Cheifetz, A. S. & Moss, A. C. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): A meta-Analysis. Am. J. Gastroenterol. 108, 40-47 (2013).
33. Allez, M. et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects. J. Crohns Colitis 4, 355-366 (2010).
34. Ben-Horin, S. & Chowers, Y. Loss of response to anti-TNF treatments in Crohn's disease. Aliment. Pharmacol. Ther. 33, 987-995 (2011).
35. Hibi, T. et al. C reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease. J. Gastroenterol. http://dx.doi.org/10.1007/s00535-013-0807-0.
36. Ungar, B. et al. The temporal evolution of antidrug antibodies in inflammatory bowel disease patients treated with infliximab. Gut http://dx.doi.org/10.1136/gutjnl-2013-305259.
37. Steenholdt, C. et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 18, 2209-2217 (2012).
38. Vande Casteele, N. et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am. J. Gastroenterol. 108, 962-971 (2013).
39. Lallemand, C. et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNF α antagonists. J. Immunol. Methods 373, 229-239 (2011).
40. Vande Casteele, N. et al. Detection of infliximab levels and anti-infliximab antibodies: A comparison of three different assays. Aliment. Pharmacol. Ther. 36, 765-771 (2012).
41. Kopylov, U. et al. The clinical utility of anti human lambda chain-based ELISA versus double antigen ELISA for the detection of anti-Infliximab antibodies. Inflamm. Bowel Dis. 18, 1628-1633 (2012).
42. Bendtzen, K. et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab. Arthritis Rheum. 54, 3782-3789 (2006).
43. Steenholdt, C. et al. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease. Ther. Drug Monit. 35, 530-538 (2013).
44. Steenholdt, C. et al. Secondary infliximab treatment failure in Crohn's disease: Therapeutic implications of measuring drug and anti-drug antibodies by three different binding assays. Gastroenterology 144 (Suppl. 1), S773 (2013).
45. Büttel, I. C. et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 39, 100-109 (2011).
46. Mould, D. R. & Green, B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: Concepts and lessons for drug development. BioDrugs 24, 23-39 (2010).
47. Ordás, I., Mould, D. R., Feagan, B. G. & Sandborn, W. J. Anti-TNF monoclonal antibodies in inflammatory bowel disease: Pharmacokinetics-based dosing paradigms. Clin. Pharmacol. Ther. 91, 635-646 (2012).
48. Tabrizi, M., Bornstein, G. G. & Suria, H. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J. 12, 33-43 (2010).
49. Takeuchi, T. et al. Baseline tumour necrosis factor α levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70, 1208-1215 (2011).
50. Olsen, T., Goll, R., Cui, G., Christiansen, I. & Florholmen, J. TNF-α gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine 46, 222-227 (2009).
51. Chaudhury, C. et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan J. Exp. Med. 197, 315-322 (2003).
52. Suzuki, T. et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: A comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J. Immunol. 184, 1968-1976 (2010).
53. Hansen, R. J. & Balthasar, J. P. Intravenous immunoglobulin mediates an increase in anti-platelet antibody clearance via the FcRn receptor. Thromb. Haemost. 88, 898-899 (2002).
54. Deng, R., et al. Pharmacokinetics of humanized monoclonal anti-Tumor necrosis factor-α antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab. Dispos. 38, 600-605 (2010).
55. Fasanmade, A. A., Adedokun, O. J., Olson, A., Strauss, R. & Davis, H. M. Serum albumin concentration: A predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int. J. Clin. Pharmacol. Ther. 48, 297-308 (2010).
56. Fasanmade, A. A. et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur. J. Clin. Pharmacol. 65, 1211-1228 (2009).
57. van Bilsen, K. et al. The neonatal Fc receptor is expressed by human retinal pigment epithelial cells and is downregulated by tumour necrosis factor-α. Br. J. Ophthalmol. 95, 864-868 (2011).
58. Liu, X. et al. NF κB signaling regulates functional expression of the MHC class I related neonatal Fc receptor for IgG via intronic binding sequences. J. Immunol. 179, 2999-3011 (2007).
59. Louis, E. et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment. Pharmacol. Ther. 19, 511-519 (2004).
60. Brandse, J. F. et al. Fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease. J. Crohns Colitis 7 (Suppl. 1), S210 (2013).
61. Hanauer, S. B. et al. Human anti-Tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC I trial. Gastroenterology 130, 323-333 (2006).
62. Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383-1395 (2010).
63. Ben-Horin, S., Kopylov, U. & Chowers, Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun. Rev. 13, 24-30 (2013).
64. Caporali, R. et al. Treatment of rheumatoid arthritis with anti TNF α agents: A reappraisal. Autoimmun. Rev. 8, 274-280 (2009).
65. Zorzi, F. Efficacy and safety of infliximab and adalimumab in Crohn's disease: A single centre study. Aliment. Pharmacol. Ther. 35, 1397-1407 (2012).
66. Arnott, I. D., McNeill, G. & Satsangi, J. An analysis of factors influencing short-Term and sustained response to infliximab treatment for Crohn's disease. Aliment. Pharmacol. Ther. 17, 1451-1457 (2003).
67. Sprakes, M. B., Ford, A. C., Warren, L., Greer, D. & Hamlin, J. Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: A large single centre experience. J. Crohns Colitis 6, 143-153 (2012).
68. Siegel, C. A. & Melmed, G. Y. Predicting response to anti-TNF agents for the treatment of Crohn's disease. Ther. Adv. Gastroenterol. 2, 244-251 (2009).
69. Ferrante, M. et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm. Bowel Dis. 13, 123-128 (2007).
70. Lee, K. M. et al. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study. J. Gastroenterol. Hepatol. 28, 1829-1833 (2013).
71. Sandborn, W. J. et al. Exploring the use of adalimumab for patients with moderate Crohn's disease: Subanalyses from induction and maintenance trials. J. Crohns Colitis 7, 958-967 (2013).
72. Steenholdt, C. et al. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease. Aliment. Pharmacol. Ther. 37, 1172-1183 (2013).
73. Rismo, R. et al. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand. J. Gastroenterol. 47, 538-547 (2012).
74. Vermeire, S. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 123, 106-111 (2002).
75. Hlavaty, T. et al. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 22, 613-626 (2005).
76. Arijs, I. et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease. Inflamm. Bowel Dis. 16, 2090-2098 (2010).
77. Arijs, I. et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 58, 1612-1619 (2009).
78. Nattiv, R., Wojcicki, J. M., Garnett, E. A., Gupta, N. & Heyman, M. B. High-dose infliximab for treatment of pediatric ulcerative colitis: A survey of clinical practice. World J. Gastroenterol. 18, 1229-1234 (2012).
79. Van Moerkercke, W. et al. High infliximab trough levels are associated with mucosal healing in Crohn's disease. Gastroenterology 138 (Suppl. 1), S60 (2010).
80. Zintzaras, E., Dahabreh, I. J., Giannouli, S., Voulgarelis, M. & Moutsopoulos, H. M. Infliximab and methotrexate in the treatment of rheumatoid arthritis: A systematic review and meta-Analysis of dosage regimens. Clin. Ther. 30, 1939-1955 (2008).
81. Kevans, D., Murthy, S., Iacono, A., Silverberg, M. S. & Greenberg, G. R. Accelerated clearance of serum infliximab during induction therapy for acute ulcerative colitis is associated with treatment failure. Gastroenterology 142 (Suppl. 1), S385 (2012).
82. Ho, G. T. et al. The use of adalimumab in the management of refractory Crohn's disease. Aliment. Pharmacol. Ther. 27, 308-315 (2008).
83. Swaminath, A. et al. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-Treated and naïve patients. Aliment. Pharmacol. Ther. 29, 273-278 (2009).
84. Allez, M. et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment. Pharmacol. Ther. 31, 92-101 (2010).
85. Chaparro, M. et al. Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J. Gastroenterol. 18, 5219-5224 (2012).
86. Kekow, J., Mueller-Ladner, U. & Schulze-Koops, H. Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure. Biologics 6, 191-199 (2012).
87. Lin, Z., Bai, Y. & Zheng, P. Meta-Analysis: Efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease. Eur. J. Gastroenterol. Hepatol. 23, 1100-1110 (2011).
88. Gisbert, J. P. & Panes, J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review. Am. J. Gastroenterol. 104, 760-767 (2009).
89. Billioud, V., Sandborn, W. J. & Peyrin-Biroulet, L. Loss of response and need for adalimumab dose intensification in Crohn's disease. A systematic review. Am. J. Gastroenterol. 106, 674-684 (2011).
90. Kestens, C. et al. Adalimumab and infliximab are equally effective for Crohn's disease in patients not previously treated with anti-Tumor necrosis factor α agents. Clin. Gastroenterol. Hepatol. 11, 826-831 (2013).
91. Osterman, M. T. et al. Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin. Gastroenterol. Hepatol. http://dx.doi.org/10.1016/j.cgh.2013.06.010.
92. Lichtenstein, G. R. et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128, 862-869 (2005).
93. Schnitzler, F. et al. Long-Term outcome of treatment with infliximab in 614 patients with Crohn's disease: Results from a single-centre cohort. Gut 58, 492-500 (2009).
94. Rutgeerts, P. et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126, 402-413 (2004).
95. Vermeire, S. et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56, 1226-1231 (2007).
96. Van Assche, G. et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: A randomized trial. Gastroenterology 134, 1861-1868 (2008).
97. Feagan, B. G. et al. A randomized trial of methotrexate (MTX) in combination with infliximab (IFX) for the treatment of Crohn's disease (CD). Gastroenterology 134 (Suppl. 1), 682c (2008).
98. Panaccione R. et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: The UC SUCCESS trial. J. Crohns Colitis 5, 2 (2011).
99. Siegel, C. A., Finlayson, S. R., Sands, B. E. & Tosteson, A. N. Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin. Gastroenterol. Hepatol. 10, 46-51 (2012).
100. Sokol, H. et al. Usefulness of co-Treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 59, 1363-1368 (2010).
101. van der Valk, M. E., van Oijen, M. G., Ammerlaan, M., Siersema, P. D. & Oldenburg, B. Crohn's disease patients treated with adalimumab benefit from co-Treatment with immunomodulators. Gut 61, 324-325 (2012).
102. Reenaers, C. et al. Does co-Treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab? Aliment. Pharmacol. Ther. 36, 1040-1048 (2012).
103. Baert, F. et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients. J. Crohns Colitis 7, 154-160 (2013).
104. Kiss, L. S. et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment. Pharmacol. Ther. 34, 911-922 (2011).
105. Abraham, N. S., Richardson, P., Castillo, D. & Kane, S. V. WITHDRAWN: Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. http://dx.doi.org/10.1016/j.cgh.2013.06.004.
106. Melmed, G. Y. et al. The appropriateness of concomitant immunomodulators with anti-Tumor necrosis factor agents for Crohn's disease: One size does not fit all. Clin. Gastroenterol. Hepatol. 8, 655-659 (2010).
107. Kamm, M. A., Ng, S. C., De Cruz, P., Allen, P. & Hanauer, S. B. Practical application of anti-TNF therapy for luminal Crohn's disease. Inflamm. Bowel Dis. 17, 2366-2391 (2011).
108. Khanna, R. et al. Review article: A clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment. Pharmacol. Ther. 38, 447-459 (2013).
109. Denis, M. A., Reenaers, C., Fontaine, F., Belaïche, J. & Louis, E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C reactive protein serum level. Inflamm. Bowel Dis. 13, 1100-1105 (2007).
110. Sandborn, W. J. et al. Dosage adjustment during long-Term adalimumab treatment for Crohn's disease: Clinical efficacy and pharmacoeconomics. Inflamm. Bowel Dis. 17, 141-151 (2011).
111. Billioud, V. et al. Adherence to adalimumab therapy in Crohn's disease: A French multicenter experience. Inflamm. Bowel Dis. 17, 152-159 (2011).
112. Lopez, A., Billioud, V., Peyrin-Biroulet, C. & Peyrin Biroulet, L. Adherence to anti-TNF therapy in inflammatory bowel diseases: A systematic review. Inflamm. Bowel Dis. 19, 1528-1533 (2013).
113. Kopylov, U. et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of Infliximab. Aliment. Pharmacol. Ther. 33, 349-357 (2011).
114. Katz, L. et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm. Bowel Dis. 18, 2026-2033 (2012).
115. St Clair, E. W. et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a mulitcenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46, 1451-1459 (2002).
116. Ben-Bassat, O. et al. Serum adalimumab and immunogenicity in IBD patients after 80 mg biweekly maintenance therapy. Gastroenterology 144 (Suppl. 1), S771 (2013).
117. van der Valk, M. E. et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: Results from the COIN study. Gut http://dx.doi.org/10.1136/gutjnl-2012-303376.
118. Irving, P., Sastrillo, M., Duncan, J., Anderson, S. & Sanderson, J. Effectiveness of temporary dose increase at recapturing response in patients on maintenance infliximab. Gut 60 (Suppl. 1), A204 (2011).
119. Sandborn, W. J. et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial. Ann. Intern. Med. 146, 829-838 (2007).
120. Ma, C. et al. Systematic review: The short-Term and long-Term efficacy of adalimumab following discontinuation of infliximab. Aliment. Pharmacol. Ther. 30, 977-986 (2009).
121. Hibi, T. et al. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease. Inflamm. Bowel Dis. 18, 1480-1487 (2012).
122. Afif, W. et al. Clinical utility of measuring Infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am. J. Gastroenterol. 105, 1133-1139 (2010).
123. Pariente, B. et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 18, 1199-1206 (2012).
124. Bendtzen, K., Ainsworth, M., Steenholdt, C., Thomsen, O. O. & Brynskov, J. Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-Tumour necrosis factor-α antibodies. Scand. J. Gastroenterol. 44, 774-781 (2009).
125. Colombel, J. F., Feagan, B. G., Sandborn, W. J., Van Assche, G. & Robinson, A. M. Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm. Bowel Dis. 18, 349-358 (2012).
126. Yanai, H. & Hanauer, S. B. Assessing response and loss of response to biological therapies in IBD. Am. J. Gastroenterol. 106, 685-698 (2011).
127. Ordás, I., Feagan, B. G. & Sandborn, W. J. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 10, 1079-1087 (2012).
128. Ben-Horin, S. et al. Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 11, 444-447 (2013).
129. Ben-Horin, S. et al. Thiopurines' delayed-onset of the anti-inflammatory effect: Early preservation of immune effector functions followed by eventual memory cell depletion. Gut 58, 396-403 (2009).
130. Sands, B. E. et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. Inflamm. Bowel Dis. 13, 2-11 (2007).
131. Steenholdt, C. et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: A randomised, controlled trial. Gut http://dx.doi.org/10. 1136/gutjnl-2013-305279.
132. Velayos, F. S., Kahn, J. G., Sandborn, W. J. & Feagan, B. G. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab. Clin. Gastroenterol. Hepatol. 11, 654-666 (2013).
133. Louis, E. et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 142, 63-70 (2012).
134. Armuzzi, A. et al. Long-Term scheduled therapy with infliximab in inflammatory bowel disease: A single-centre observational study. Gastroenterology 5 (Suppl. 1), s691-s692 (2010).
135. Waugh, A. W. et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: Long-Term follow-up of a single centre cohort. Aliment. Pharmacol. Ther. 32, 1129-1134 (2010).
136. Molnár, T. et al. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy. Aliment. Pharmacol. Ther. 37, 225-233 (2013).
137. Baszis, K. et al. Clinical outcomes after withdrawal of anti-Tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: A twelve-year experience. Arthritis Rheum. 63, 3163-3168 (2011).
138. Tanaka, Y. et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann. Rheum. Dis. 69, 1286-1291 (2010).
139. Domènech, E. et al. Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen. J. Clin. Gastroenterol. 44, 34-37 (2010).
140. Brocq, O. et al. Effect of discontinuing TNFα antagonist therapy in patients with remission of rheumatoid arthritis. Joint Bone Spine 76, 350-355 (2009).
141. Oussalah, A. et al. Predictors of infliximab failure after azathioprine withdrawal in Crohn's disease treated with combination therapy. Am. J. Gastroenterol. 105, 1142-1149 (2010).
142. Regueiro, M. et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 136, 441-450 (2009).
143. Sorrentino, D. et al. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin. Gastroenterol. Hepatol. 8, 591-599 (2010).
144. Vande Casteele, N. et al. Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled trough level adapted infliximab treatment (TAXIT) trial. J. Crohns Colitis 6, S6 (2012).
145. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01442025 (2013).
146. Imaeda, H. et al. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J. Gastroenterol. http://dx.doi.org/10.1007/s00535-013- 0829-7.
147. Ben-Horin, S. et al. The decline of anti-drug antibody titers after discontinuation of anti-TNFs: Implications for predicting re-induction outcome in IBD. Aliment. Pharmacol. Ther. 35, 714-722 (2012).
148. Baert, F. et al. Early trough levels and antibodies predict safety and success of restarting infliximab after long drug holiday. Gastroenterology 5 (Suppl. 1), s62 (2011).
149. Steenholdt, C. et al. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: An observational Danish single center study. Scand. J. Gastroenterol. 47, 518-527 (2012).